Stamcellegenetik

Question 1

Turnover

Answer 1

-

Question 2

Pluripotente celler

Answer 2

-

Question 3

Totipotente celler

Answer 3

-

Question 4

Multipotente celler

Answer 4

-

Question 5

Oligopotente celler

Answer 5

-

Question 6

Unipotente celler

Answer 6

-

Question 7

Genetisk behandling af recessiv loss-of-function mutation

Answer 7

Tilførsel af nyt gen vha. genterapi

Question 8

Genetisk behandling af dominant gain-of-function mutation

Answer 8

Reperation af mutationer (konventionel metode) eller knockout (CRISPR)

Question 9

In vivo

Answer 9

I kroppen

Question 10

Ex vivo

Answer 10

Udenfor kroppen

Question 11

Retrovirale vektorer

Answer 11

Integreres i genomet. Bruges til behandling af stamceller, der laver meget celledeling. Risiko for aktivere proto-onkogener

Question 12

Lentivariale vektorer

Answer 12

Integreres i genomet. Bruges til behandling af stamceller, der laver meget celledeling

Question 13

AAV adeno associeret virus

Answer 13

Integreres ikke i genomet. Bruges til in vivo behandling af celler, der ikke laver meget celle deling.

Question 14

Serotype

Answer 14

Den virale vektors “kappe”

Question 15

NHEJ

Answer 15

-

Question 16

HDR

Answer 16

-

Question 17

Cas9

Answer 17

-

Question 18

sgRNA

Answer 18

Guide RNA…

Question 19

PAM-sekvens

Answer 19

-

Question 20

Geneditering

Answer 20

-

Question 21

In vivo

Answer 21

I kroppen

Question 22

Ex vivo

Answer 22

Udenfor kroppen

Question 23

In vitro

Answer 23

I cellekultur

Question 24

Episomal

Answer 24

Når virus’ DNA ikke integreres i værtscellens genom. Gælder AAV vektor

Question 25

I celler/væv, der deler meget, genediteres typisk i

Answer 25

Stamceller

Question 26

I celler/væv, der ikke deler meget, genediteres typisk i

Answer 26

Selve vævet og episomalt

Question 27

Off-targets

Answer 27

- Sker når RNA, DNA eller protein indsættes?